Potential mechanism of Astragalus polysaccharide increasing chemosensitivity of cervical cancer HeLa cells to carboplatin by modulating the PI3K/Akt signaling pathway

The current study investigated the possible mechanisms in which astragalus polysac-charide (APS) elevates the chemosensitivity of cervical cancer (CC) HeLa cells to carboplatin (CBP) by regulating the PI3K/Akt pathway. In this study, HeLa cells were assigned to the control, CBP, APS, and APS + CBP groups, and the proliferation of HeLa cells in each group was detected using the MTT (methyl thiazolyl tetrazolium) assay. The apoptosis and cycle of HeLa cells were examined using flow cytometry, and the expression levels of PI3K (phosphatidylinositol-3-kinases), Akt (Protein Kinase B), p-PI3K (phospho-phosphatidylinositol-3-kinases), and p-Akt (phospho-Akt) proteins in the PI3K/Akt pathway were determined using Western blot. MTT results revealed that the inhibitory effect was more significant within the APS + CBP groups (p < 0.01). The flow cytometry results showed that the apoptosis rate was significantly elevated in the APS + CBP groups (p < 0.01). Compared with the control group, the most prominent arrest in the G2/M phase and the arrest within the G2/M phase in the APS + CBP groups being the most significant. Western-blot results depicted that the above proteins in the APS + CBP groups revealed more significant expression changes (p < 0.01). The above analyses demonstrated that APS could increase the chemosensitivity of CC HeLa cells to CBP by modulating the PI3K/Akt pathway. In conclusions, it is reasonable to believe that the enhancing effect of APS on the sensitivity of chemotherapeutic drugs was associated with blocking the PI3K/Akt pathway, thus, enhancing.

Cervical cancer; PI3K/Akt pathway; Chemosensitivity; Astragalus polysaccharide; HeLa cells

[1] Song D, Kong W, Zhang T, Han C, Liu T, Jiao S, et al. A retrospective analysis of cisplatin/carboplatin plus paclitaxel in advanced or recurrent cervical cancer. Journal of Obstetrics and Gynaecology. 2019; 39: 389–394.

[2] Choudhari AS, Mandave PC, Deshpande M, Ranjekar P, Prakash O. Phytochemicals in cancer treatment: from preclinical studies to clinical practice. Frontiers in Pharmacology. 2020; 10: 1614.

[3] Guo Y, Zhang Z, Wang Z, Liu G, Liu Y, Wang H. Astragalus polysaccharides inhibit ovarian cancer cell growth via microRNA-27a/FBXW7 signaling pathway. Bioscience Reports. 2020; 40: BSR20193396.

[4] Bamodu OA, Kuo K-T, Wang C-H, Huang W-C, Wu ATH, Tsai J-T, et al. Astragalus polysaccharides (PG2) enhances the M1 polarization of macrophages, functional maturation of dendritic cells, and T cell-mediated anticancer immune responses in patients with lung cancer. Nutrients. 2019; 11: 2264.

[5] Huang W-C, Kuo K-T, Bamodu OA, Lin Y-K, Wang C-H, Lee K-Y, et al. Astragalus polysaccharide (PG2) ameliorates cancer symptom clusters, as well as improves quality of life in patients with metastatic disease, through modulation of the inflammatory cascade. Cancers. 2019; 11: 1054.

[6] Wu C, Ke Y, Zeng Y, Zhang Y, Yu H. Anticancer activity of Astragalus polysaccharide in human non-small cell lung cancer cells. Cancer Cell International. 2017; 17: 115.

[7] Li C, Hong L, Liu C, Min J, Hu M, Guo W. Astragalus polysaccharides increase the sensitivity of SKOV3 cells to cisplatin. Archives of Gynecology and Obstetrics. 2018; 297: 381–386.

[8] Tan Y, Yin L, Sun Z, Shao S, Chen W, Man X, et al. Astragalus polysaccharide exerts anti-Parkinson via activating the PI3K/AKT/mTOR pathway to increase cellular autophagy level in vitro. International Journal of Biological Macromolecules. 2020; 153: 349–356.

[9] Zhai Q, Hu X, Xiao J, Yu D. Astragalus polysaccharide may increase sensitivity of cervical cancer HeLa cells to cisplatin by regulating cell autophagy. China Journal of Chinese Materia Medica. 2018; 43: 805–812. (In Chinese)

[10] Shi Y, Feng X, Xie L, Wang X. Research progress on PI3K/AKT signal transduction pathway in tumors. Chemistry of Life. 2018; 38: 421–426.

[11] Zhang Z, Wang Z, Hao M. The research progress of PI3K/AKT/mTOR signal pathway in gynecologic malignancies. World Latest Medicine Information. 2018; 18: 85–87,92. (In Chinese)

[12] Li T, Zhou Q, Zhang W. Advances in research of PI3K/Akt/mTOR signaling pathway for treatment of triple negative breast cancer. China Cancer. 2018; 27: 40–45. (In Chinese)

[13] Liu W, Li G. Research progress of PI3K/Akt signaling pathway and tumor multidrug resistance. Journal of Modern Medicine and Health. 2017; 33: 225–227.

[14] Zhou H, Liu Y, Luo M, Lin Z. Interpretation of 2022 NCCN Clinical Practice Guidelines to Cervical Cancer (1st edition). Chinese Journal of Practical Gynecology and Obstetrics. 2021; 37: 1220–1226.

[15] Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR signaling in cancer. Frontiers in Oncology. 2014; 4: 64.

[16] Xia P, Xu X-Y. PI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical application. American Journal of Cancer Research. 2015; 5: 1602.

[17] Aoki M, Fujishita T. Oncogenic Roles of the PI3K/AKT/mTOR Axis. Current Topics in Microbiology and Immunology. 2017; 71: 153–189.

[18] Ersahin T, Tuncbag N, Cetin-Atalay R. The PI3K/AKT/mTOR interactive pathway. Molecular BioSystems. 2015; 11: 1946–1954.

[19] Lien EC, Dibble CC, Toker A. PI3K signaling in cancer: beyond AKT. Current Opinion in Cell Biology. 2017; 45: 62–71.

[20] Noorolyai S, Shajari N, Baghbani E, Sadreddini S, Baradaran B. The relation between PI3K/AKT signalling pathway and cancer. Gene. 2019; 698: 120–128.

[21] Yang Q, Jiang W, Hou P. Emerging role of PI3K/AKT in tumor-related epigenetic regulation. Seminars in Cancer Biology. 2019; 59: 112–124.

[22] Pompura SL, Dominguez-Villar M. The PI3K/AKT signaling pathway in regulatory T-cell development, stability, and function. Journal of Leukocyte Biology. 2018; 103: 1065–1076.

[23] Xie Y, Shi X, Sheng K, Han G, Li W, Zhao Q, et al. PI3K/Akt signaling transduction pathway, erythropoiesis and glycolysis in hypoxia. Molecular Medicine Reports. 2019; 19: 783–791.

[24] Karar J, Maity A. PI3K/AKT/mTOR pathway in angiogenesis. Frontiers in Molecular Neuroscience. 2011; 4: 51.

[25] Cao Y, Ruan Y, Shen T, Huang X, Li M, Yu W, et al. Astragalus polysaccharide suppresses doxorubicin-induced cardiotoxicity by regulating the PI3k/Akt and p38MAPK pathways. Oxidative Medicine and Cellular Longevity. 2014; 2014: 674219.

[26] Zhang Y, Wang L, Du M. Research progress on treatment of tumor with Astragalus polysaccharides for injection. Drug Evaluation Research. 2016; 39: 1092–1094. (In Chinese)

[27] Sun S, He X, Luo D, Lv C, Jing S, Lv A, et al. Synergism and attenuation effect of Astragalus Polysaccharide on cisplatin in the treatment of mice bearing S180 tumor. Chinese Journal of Basic Medicine in Traditional Chinese Medicine. 2013; 19: 787–789. (In Chinese)

[28] Zhang M, Li W, Zhao P, Gao W, Huo L, Sui A, et al. Effect of Astragalus polysaccharides on immunologic function of gastric cancer patients with postoperative adjuvant chemotherapy. Guangdong Medical Journal. 2018; 39: 3543–3547. (In Chinese)

[29] Zhang M, Zhang C, Liu X, Li W, Gao W, Sui A, et al. Effect and significance of astragalus polysaccharide on serum inflammatory factors in patients with postoperative adjuvant chemotherapy for gastric cancer. Chinese Journal of Gerontology. 2020; 40: 768–771. (In Chinese)

[30] Yang YL, Lin ZW, He PT, Nie H, Yao QY, Zhang SY. Inhibitory effect of Astragalus Polysaccharide combined with cisplatin on cell cycle and migration of nasopharyngeal carcinoma cell lines. Biological and Pharmaceutical Bulletin. 2021; 44: 926–931.

[31] Guo L, Bai S, Zhao L, Wang X. Astragalus polysaccharide injection integrated with vinorelbine and cisplatin for patients with advanced non-small cell lung cancer: effects on quality of life and survival. Medical Oncology. 2012; 29: 1656–1662.

[32] Tian Q, Yan M, Cai H, Tan Q, Zhang W. Astragalus polysaccharides can regulate cytokine and P-glycoprotein expression in H22 tumor-bearing mice. World Journal of Gastroenterology. 2012; 18: 7079–7086.